Pramlintide vs Tirzepatide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Pramlintide vs Tirzepatide: Tirzepatide has the stronger overall evidence (7.8 vs 5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Tirzepatide Edges Ahead

Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Pramlintide0 wins

Tirzepatide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Pml5.0

Pramlintide

Too few graded studiesLimited safety

Tir7.8

Tirzepatide

Too few graded studiesLimited safety

Evidence

Evidence Score

5/10

Studies: 87

Meta-analyses: 5

Level: Moderate

Evidence Score

Best7.8/10

Studies: 133

Meta-analyses: 42

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies45
Weight managementToo few graded studies26
Safety & adverse effectsToo few graded studies8

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies80
Glycemic & metabolic controlToo few graded studies53
Heart & blood pressureToo few graded studies20

Shared outcomes (2)

Outcomes where both Pramlintide and Tirzepatide have evidence — compare verdict strength side-by-side.

Weight managementToo few graded studies26Too few graded studies80
Glycemic & metabolic controlToo few graded studies45Too few graded studies53

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-titrated. Subcutaneous injection immediately before major meals. Type 1 diabetes: typically start 15 µg and titrate to 30-60 µg per meal. Type 2 diabetes (on mealtime insulin): typically start 60 µg and titrate to 120 µg per meal. Reduce mealtime insulin (often by ~50%) when starting. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG (brand Symlin), not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA BOXED WARNING: severe insulin-induced hypoglycemia. Pramlintide is co-administered with insulin and can cause severe hypoglycemia, particularly in type 1 diabetes, and when it occurs it is seen within 3 hours following a pramlintide injection. Severe hypoglycemia can impair the ability to drive or operate machinery. Patient selection, intensive glucose monitoring, and education are essential.
Mealtime (premeal) insulin must be reduced — typically by about 50% — when initiating pramlintide, then re-titrated under clinician guidance.
Nausea is the most common adverse effect (often with anorexia/vomiting at higher doses), usually mild-to-moderate and concentrated in the first weeks; gradual titration reduces it.
Inject pramlintide SEPARATELY from insulin — the two cannot be mixed in the same syringe (different pH).
Do NOT use if a meal is skipped, or in people with gastroparesis or hypoglycemia unawareness.
Slowed gastric emptying can delay absorption of co-administered oral drugs — separate rapidly-acting oral medications from the injection.
Efficacy is modest — it complements insulin, it does not replace it.
Not a weight-loss supplement or shortcut — its weight effect is modest and inseparable from its prescription-drug risk profile.

Best Time:

With meals

Take with food

Best Form:

Subcutaneous pre-meal injection (Symlin / SymlinPen)

Recommended Dosage:

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.
Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.
A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.
FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.
Not for cosmetic or off-label use without a medical indication and supervision.
May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.
Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

Safety

Limited safetyTie

Drug Interactions:

Insulin (mealtime / prandial) (severe)
Other glucose-lowering agents (sulfonylureas, etc.) (moderate)
Oral medications requiring rapid absorption (moderate)

and 1 more not shown

Side Effects:

Severe insulin-induced hypoglycemiaNauseaVomiting / anorexia

Contraindications:

Confirmed diagnosis of gastroparesis (slowed gastric emptying would be worsened)
Hypoglycemia unawareness

Limited safetyTie

Drug Interactions:

Oral contraceptives (moderate)
Insulin and sulfonylureas (moderate)
Oral medications generally (moderate)

Side Effects:

NauseaDiarrheaVomiting

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Shared goals

Manage weightTirzepatide

Pramlintide48/100

Tirzepatide90/100

Manage blood sugarTirzepatide

Pramlintide56/100

Tirzepatide85/100

What you'll notice

🩸 Modest HbA1c reductionpositive

Weeks to 6-12 months

📉 Lower postprandial glucosepositive

Per meal / weeks

⚖️ Modest weight losspositive

Months

⚠️ Severe insulin-induced hypoglycemia (US FDA boxed warning)trade-off

The label describes severe hypoglycaemia, when it occurs, within three hours after a Symlin injection; this is not a guarantee of no risk at other times.

🩸 Strong glycemic controlpositive

Weeks to months

⚖️ Large weight losspositive

Months (dose-escalated over ~20 weeks)

😴 Reduced sleep-apnea severitypositive

Weeks to months

🤢 GI side effects (common)negative

Mostly during titration

Key studies

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Diabet Med (2004) · Rct · n=651

Double-blind, placebo-controlled, parallel-group multicentre trial in 651 patients with type 1 diabetes, mealtime pramlintide at varying doses or placebo added to insulin for 52 weeks.

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Diabetes Care (2002) · Rct · n=480

52-week double-blind, placebo-controlled trial in 480 patients with type 1 diabetes, pramlintide 30 µg four times daily or placebo added to insulin. At week 20, pramlintide patients whose HbA1c had fallen less than 1% by week 13 were re-randomised to 30 or 60 µg.

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Diabetes Care (2003) · Rct · n=656

52-week double-blind, placebo-controlled, parallel-group multicentre trial in 656 insulin-treated patients with type 2 diabetes, randomised to placebo or pramlintide 60 µg three times daily, 90 µg twice daily or 120 µg twice daily.

All Pramlintide studies

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=1879

Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med (2022) · Rct · n=2539

72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

N Engl J Med (2025) · Rct · n=751

Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide

All Tirzepatide studies

Frequently asked questions

Is Pramlintide better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 5/10) and wins in 2 of 3 categories.

Is Pramlintide or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 48).

Can I take Pramlintide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Iron vs Pramlintide Pramlintide vs Whey Protein Pramlintide vs Semaglutide Semaglutide vs Tirzepatide Liraglutide vs Tirzepatide Thiamine vs Tirzepatide

Still deciding between Pramlintide and Tirzepatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Pramlintide details Tirzepatide details

Warnings

This is a PRESCRIPTION DRUG (brand Symlin), not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA BOXED WARNING: severe insulin-induced hypoglycemia. Pramlintide is co-administered with insulin and can cause severe hypoglycemia, particularly in type 1 diabetes, and when it occurs it is seen within 3 hours following a pramlintide injection. Severe hypoglycemia can impair the ability to drive or operate machinery. Patient selection, intensive glucose monitoring, and education are essential.

Mealtime (premeal) insulin must be reduced — typically by about 50% — when initiating pramlintide, then re-titrated under clinician guidance.

Nausea is the most common adverse effect (often with anorexia/vomiting at higher doses), usually mild-to-moderate and concentrated in the first weeks; gradual titration reduces it.

Inject pramlintide SEPARATELY from insulin — the two cannot be mixed in the same syringe (different pH).

Do NOT use if a meal is skipped, or in people with gastroparesis or hypoglycemia unawareness.

Slowed gastric emptying can delay absorption of co-administered oral drugs — separate rapidly-acting oral medications from the injection.

Efficacy is modest — it complements insulin, it does not replace it.

Not a weight-loss supplement or shortcut — its weight effect is modest and inseparable from its prescription-drug risk profile.

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.

Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.

A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.

FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.

Not for cosmetic or off-label use without a medical indication and supervision.

May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.

Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Frequently asked questions

Is Pramlintide better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 5/10) and wins in 2 of 3 categories.

Is Pramlintide or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 48).

Can I take Pramlintide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.